selatogrel

a P2Y12 receptor antagonist; structure in first source

Also Known As:

((2R)-3-(4-butoxycarbonylpiperazin-1-yl)-2-((6-((3S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl)amino)-3-oxopropyl)phosphonic acid; ACT-246475

Networked: 12 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - selatogrel: 12
Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphonates: 424
    - selatogrel: 12

Experts

1.	Dingemanse, Jasper: 4 articles (01/2022 - 01/2020)
2.	Riederer, Markus A: 3 articles (11/2021 - 10/2017)
3.	Caroff, Eva: 3 articles (01/2021 - 10/2017)
4.	Ufer, Mike: 3 articles (04/2020 - 01/2020)
5.	Krause, Andreas: 2 articles (01/2022 - 01/2021)
6.	Schilling, Uta: 2 articles (01/2022 - 01/2020)
7.	Baumann, Martine: 2 articles (11/2021 - 10/2017)
8.	Crescence, Lydie: 2 articles (11/2021 - 01/2021)
9.	Dubois, Christophe: 2 articles (11/2021 - 01/2021)
10.	Kramberg, Markus: 2 articles (11/2021 - 10/2017)

Related Diseases

1.	Thrombosis (Thrombus) 11/17/2021 - "Therefore, our experiments uncovered a novel advantage of selatogrel: the dissolution of pre-formed thrombi without the disintegration of haemostatic seals, suggesting a bipartite benefit of the early application of selatogrel in patients with acute thrombosis." 11/17/2021 - "The infusion of selatogrel during ongoing platelet thrombus formation stopped growth and induced the dissolution of the preformed platelet thrombus. " 11/17/2021 - "Selatogrel, a potent and reversible antagonist of the P2Y12 receptor, inhibited FeCl3-induced thrombosis in rats. " 11/17/2021 - "In addition, in a modified Folts thrombosis model in guinea pigs, selatogrel prevented a decrease in blood-flow, indicative of the inhibition of ongoing thrombosis, approximately 10 min after subcutaneous injection. " 10/01/2017 - "The aim of this study was to compare two direct-acting, reversible P2Y12 antagonists, ACT-246475 and ticagrelor, in a rat thrombosis model by simultaneous quantification of their antithrombotic efficacy and surgery-induced blood loss. "
2.	ST Elevation Myocardial Infarction 11/01/2023 - "In this study, we evaluated two injectable platelet inhibitors under clinical development (the P2Y12 antagonist selatogrel and the GPIIb-IIIa antagonist zalunfiban) that may be amenable to pre-hospital treatment of STEMI patients. "
3.	Myocardial Infarction 07/01/2023 - "Selatogrel, a 2-phenylpyrimidine-4-carboxamide analog, is a potent, reversible, and selective P2Y12 inhibitor administered subcutaneously that is under development for the treatment of acute myocardial infarction (AMI) in patients with a recent history of AMI. " 01/01/2021 - "Selatogrel shows rapid onset and offset of inhibition of platelet aggregation (IPA) to overcome the critical initial time after acute myocardial infarction. " 01/01/2020 - "Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction." 01/01/2020 - "Selatogrel is characterized by a rapid onset of action following subcutaneous administration and developed for early treatment of a suspected acute myocardial infarction. " 07/01/2023 - "Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction."
4.	Hemorrhage 01/01/2020 - "Selatogrel was well tolerated, without major bleeding complications. "

Related Drugs and Biologics

1.	Ticagrelor
2.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
3.	Purinergic P2Y Receptor Antagonists
4.	Thrombin
5.	Clopidogrel (Plavix)

Related Therapies and Procedures

1.	Injections
2.	Self Administration (Administration, Self)
3.	Self Medication
4.	Lasers (Laser)
5.	Subcutaneous Injections